VENUS MEDTECH-B (02500) has seen a significant rise of over 14%, reporting a gain of 14.01% to HK$2.93, with a trading volume of HK$10.77 million as of the time of this report. The company announced that the Cardiovalve transcatheter tricuspid valve replacement (TTVR) confirmatory clinical study has successfully completed the enrollment of all 150 patients. This marks a major advancement in Cardiovalve's development in treating tricuspid regurgitation, signaling a key milestone towards obtaining the CE Mark. Additionally, the mid-term results of the TARGET study will be officially announced at the PCR London Valves 2025 conference this year. The company stated that it will continue to advance clinical research, registration, and commercialization efforts for various innovative products, including Cardiovalve, on a global scale, aiming to establish a comprehensive lineup of "four valves in one" structural heart valve products, providing leading solutions for valve diseases to more patients worldwide while further deepening its international development strategy.